GNA Biosolutions Reveals New Ultrafast PCR Platform at Medical Trade Show
|
By LabMedica International staff writers Posted on 15 Nov 2017 |

Image: The Pharos V8 laser PCR platform (Photo courtesy of GNA Biosolutions).
GNA Biosolutions GmbH (Martinsried, Germany), a molecular technology company, will showcase its new Pharos V8, the world's first laser PCR platform, at MEDICA 2017.
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
GNA Biosolutions specializes in sample-to-result applications across medical diagnostics, biosecurity, food safety, and life sciences. The company develops instruments, OEM modules and applications for ultrafast molecular assays based on proprietary technology protected by a comprehensive patent portfolio.
The Pharos V8, an ultrafast PCR instrument for in vitro research use, uses the patented Laser PCR technology, which operates on the same principles as conventional nucleic acid amplification with PCR (Polymerase Chain Reaction). However, Laser PCR uses nanomaterials to control temperature cycles at the nano scale, accelerating PCR reaction times by a factor of ten and opening the door for applications in multiple time-sensitive settings.
Some of the key features of the Pharos V8 include an open platform for universal PCR assay development, ultrafast real-time nucleic acid detection in 10 minutes or less, and intuitive interface with easy-to-use software that can be accessed remotely.
“We are excited to present our first Laser PCR platform, the Pharos V8, at this year's Medica,” said Frank Krieg-Schneider, CEO of GNA Biosolutions. “We believe the Pharos V8 will demonstrate the power of our patented technology to deliver ultrafast molecular results, and pave the way for additional platforms in development for diagnostic testing and point of care.”
Related Links:
GNA Biosolutions
Latest Industry News
- Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
- Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
- Integrated DNA Technologies Expands into Clinical Diagnostics
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
Channels
Clinical Chemistry
view channel
AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Diagnosing the cause of age-related cognitive symptoms remains challenging because clinical presentations of neurodegenerative diseases often overlap, and multiple pathologies can co-occur... Read more
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read moreMolecular Diagnostics
view channel
RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Many patients with advanced solid tumors exhaust broad DNA panel testing yet still lack biomarkers that match guideline-recommended therapies, limiting access to targeted options. Expanding molecular profiling... Read more
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more




.jpg)



